We’re pleased to Welcome Dr. Michael Peterseim as our new Chief Financial Officer (CFO) at ROTOP Dr. Peterseim brings many years of experience in financial leadership and has successfully guided companies through transformation processes, strengthened performance, and executed strategic transactions, particularly in growth situations. He has worked in various B2B and B2C environments, including
I am a trained chemical-technical assistant (CTA). ROTOP offered me a role that included not only laboratory work but also regulatory affairs activities. This immediately caught my interest, as I had no prior experience in pharmaceutical regulatory affairs and there is no specific textbook-based training for this field. As a result, it was very
Every year brings new challenges due to changing regulations and requirements from legislators and the UN. I find this variety very motivating – there is no monotonous work here. In addition to my regular accounting tasks, I can also contribute to projects. My responsibilities are wide-ranging. During my time at ROTOP, I have developed
I actually came across the job posting quite by chance – and now I’ve celebrated my 5-year anniversary with ROTOP! I was particularly interested in the radiation protection aspect, having already completed a related course during my studies. I was therefore glad that my application was welcomed here and that the interview process was
We are delighted to be featured in the latest issue of VentureCapital Magazine, which spotlights the Dresden region as a high-performance hub for key players and innovators in radiopharmaceutical innovation. ROTOP Pharmaka is recognized as a leading manufacturer of radiopharmaceuticals, including an iodine-123 compound used in Parkinson’s diagnostics. The article also emphasizes the strong
RoTecPSMA® Approved in Switzerland – Expanding Access to Advanced Prostate Cancer Diagnostics We are delighted to announce that RoTecPSMA® has received marketing authorization in Switzerland, marking another important milestone in the European rollout of this innovative diagnostic solution. This approval, achieved in close collaboration with our trusted partner and marketing authorization holder medeo AG,
Team ROTOP is back from SNMMI 2025 in New Orleans and feels energized by the global momentum in radiopharmaceuticals. Team ROTOP - Jens Junker, Felix Roschke, Thomas Gottlieb and Tanmaya Joshi - just returned from SNMMI 2025 in New Orleans. This year, the event brought together nearly 8,000 professionals from across the nuclear medicine and radiopharmaceutical
First marketing authorization for RoTecPSMA® We are thrilled to announce that RoTecPSMA® has been approved in the United Kingdom! RoTecPSMA® is a technetium-99m cold kit for SPECT imaging of prostate cancer patients and the first PSMA-SPECT tracer approved in a European country. It marks a significant step forward in closing a gap in patient care,
Andrew Varghese, President USA ROTOP Pharmaka GmbH ROTOP Pharmaka GmbH is pleased to announce new investments secured from GENUI & SHS Capital along with the appointment of Andrew Varghese as its new President of ROTOP USA. Founded in 2000 and based in Dresden-Rossendorf, ROTOP is a leading manufacturer of radiopharmaceutical products. With the
Saxon radiopharmacy network nukliD® strengthens international visibility Today, Thursday 16 January 2025, leading German and international players in the field of radiopharmacy from Saxony agree to intensify their collaboration. The aim of the partners from the fields of research, industry and cluster management is to develop radiopharmacy in Saxony into a centre of innovation and
Contact
ROTOP Pharmaka GmbH
Bautzner Landstraße 400
01328 Dresden
GERMANY
Phone: +49 (0) 351 26 310 100
Email: info@rotop-pharmaka.de
Social Media
